Surgical treatment planning in newly diagnosed breast cancer patients at high risk for BRCA-1 or BRCA-2 mutation
Chung, M.A.; Cady, B.
Breast Journal 10(6): 473-474
2004
ISSN/ISBN: 1075-122X PMID: 15569200 DOI: 10.1111/j.1075-122x.2004.21666.x
Accession: 050469668
PDF emailed within 0-6 h: $19.90
Related References
Stolier, A.J.; Fuhrman, G.M.; Mauterer, L.; Bolton, J.S.; Superneau, D.W. 2004: Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation Breast Journal 10(6): 475-480Katki, H.A.; Gail, M.H.; Greene, M.H. 2007: Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families LANCET. Oncology 8(12): 1042-1043
Daniele, A.; Divella, R.; Pilato, B.; Tommasi, S.; Pasanisi, P.; Patruno, M.; Digennaro, M.; Minoia, C.; Dellino, M.; Pisconti, S.; Casamassima, P.; Savino, E.; Paradiso, A.V. 2021: Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? a Mini review Hereditary Cancer in Clinical Practice 19(1): 45
Bremer, M.; Steinmann, D.; Dork, T.; Borger, J.; Rades, D.; Karstens, J.H. 2001: Bilaterales Mammakarzinom und Lokalrezidiv: Prävalenz von BRCA-1- und BRCA-2-Genmutationen an einem unselektionierten Kollektiv - Bilateral breast cancer and local relapse: a hospital-based study of the prevalence of BRCA 1 and BRCA 2 gene Mutations Strahlentherapie und Onkologie 177(7): 325-329
Lee, C.Khoon.; Scott, C.; Lindeman, G.J.; Hamilton, A.; Lieschke, E.; Gibbs, E.; Asher, R.; Badger, H.; Paterson, R.; Macnab, L.; Kwan, E.Michael.; Francis, P.A.; Boyle, F.; Friedlander, M. 2019: Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer British Journal of Cancer 120(3): 279-285
Silva, E. 2008: Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist Familial Cancer 7(1): 91-95
Huang, X.; Shao, D.; Wu, H.; Zhu, C.; Guo, D.; Zhou, Y.; Chen, C.; Lin, Y.; Lu, T.; Zhao, B.; Wang, C.; Sun, Q. 2020: Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients with Triple-Negative Breast Cancer Frontiers in Oncology 10: 583314
Stagnaro, S.; Caramel, S. 2013: BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention Frontiers in Genetics 4: 39
Sela, E.; Bitteman, A.; Fares, F.; Kovacs, Z.; Peleg, T.; Renart, G.; Lefel, O.; Willhelm, R.; Cohen, O. 2000: Brca-1 and brca-2 gene mutation in male breast cancer European Surgical Research 32(Suppl 1): 95
Tung, N. 2011: Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer JAMA 305(21): 2211-2220
Senkus-Konefka, E.; Domchek, S.M.; Im, S.A.; Xu, B.; Armstrong, A.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Conte, P.; Wu, W.; Goessl, C.; Runswick, S.; Robson, M. 2018: Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD European Journal of Cancer 92: S19-S20
Chen, B.; Zhang, G.; Li, X.; Ren, C.; Wang, Y.; Li, K.; Mok, H.; Cao, L.; Wen, L.; Jia, M.; Li, C.; Guo, L.; Wei, G.; Lin, J.; Li, Y.; Zhang, Y.; Han-Zhang, H.; Liu, J.; Lizaso, A.; Liao, N. 2020: Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer Aging 12(4): 3140-3155
Özmen, V. 2015: Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers Journal of Breast Health 11(3): 101-105
Coimbra, Joao Carlos; Pinto, Iraja Damiani; Wurdig, Norma Luiza; Do Carmo, Dermeval Aparecido 2016: P2: Snp Analysis in Brca Positive and Brca Negative Subjects with and without Breast Cancer (Brca) Reveal Central Role of Alk Snps and Tgfbeta Superfamily in Malignant Transformation Journal of Investigative Medicine 64(3): 817.3-818
Marchetti, C.; De Felice, F.; Palaia, I.; Perniola, G.; Musella, A.; Musio, D.; Muzii, L.; Tombolini, V.; Panici, P.B. 2014: Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers Bmc Women's Health 14: 150
Verma, S.; Dent, S.F.; Paquet, L.; Bitonti, L. 2016: When the BRCA test is negative-Prevention strategies in women who have no detectable mutation (BRCA-) compared to women harboring positive BRCA mutations (BRCA+) Journal of Clinical Oncology 26(15_Suppl): 1534-1534
Lee, Y.J.; Lee, S.W.; Kim, K.R.; Jung, K.H.; Lee, J.W.; Kim, Y.M. 2017: Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers Journal of Gynecologic Oncology 28(1): E3
Sun, J.; Chu, F.; Pan, J.; Zhang, Y.; Yao, L.; Chen, J.; Hu, L.; Zhang, J.; Xu, Y.; Wang, X.; Cao, W.; Xie, Y. 2022: BRCA-CRisk: a Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2022: Jco2200833
Begg, C.B.; Satagopan, J.M.; Robson, M.; Offit, K. 1999: Lifetime breast cancer risk associated with BRCA 1 and BRCA 2 mutations among patients of Ashkenazi Jewish origin American Journal of Human Genetics 65(4): A61
Webb, E. 2014: BRCA-negative women from BRCA-positive families may still be at increased risk of developing breast cancer Pharmacogenomics 15(3): 258-259